Seattle Genetics, Inc. (NASDAQ:SGEN) CFO Todd E. Simpson sold 9,638 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $52.00, for a total value of $501,176.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Todd E. Simpson also recently made the following trade(s):

  • On Monday, August 28th, Todd E. Simpson sold 4,937 shares of Seattle Genetics stock. The stock was sold at an average price of $47.89, for a total value of $236,432.93.

Seattle Genetics, Inc. (NASDAQ:SGEN) traded down 2.21% during midday trading on Friday, hitting $52.99. The company had a trading volume of 865,122 shares. Seattle Genetics, Inc. has a 52 week low of $45.31 and a 52 week high of $75.36. The stock has a 50 day moving average price of $49.79 and a 200-day moving average price of $59.61. The stock’s market capitalization is $7.58 billion.

Seattle Genetics (NASDAQ:SGEN) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. Seattle Genetics had a negative return on equity of 38.42% and a negative net margin of 52.08%. The company had revenue of $108.20 million for the quarter, compared to analyst estimates of $105.92 million. During the same period in the prior year, the company posted ($0.23) EPS. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. On average, equities analysts predict that Seattle Genetics, Inc. will post ($1.69) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/08/seattle-genetics-inc-sgen-cfo-todd-e-simpson-sells-9638-shares.html.

A number of large investors have recently made changes to their positions in the stock. Neuberger Berman Group LLC increased its position in Seattle Genetics by 0.5% during the 1st quarter. Neuberger Berman Group LLC now owns 12,630 shares of the biotechnology company’s stock valued at $794,000 after buying an additional 59 shares in the last quarter. Aperio Group LLC increased its position in Seattle Genetics by 0.3% during the 2nd quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock valued at $1,640,000 after buying an additional 91 shares in the last quarter. Eqis Capital Management Inc. increased its position in Seattle Genetics by 0.7% during the 2nd quarter. Eqis Capital Management Inc. now owns 26,258 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 177 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Seattle Genetics by 1.2% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,613 shares of the biotechnology company’s stock valued at $981,000 after buying an additional 191 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in Seattle Genetics by 1.1% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 18,400 shares of the biotechnology company’s stock valued at $952,000 after buying an additional 200 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

A number of equities analysts have issued reports on SGEN shares. ValuEngine upgraded Seattle Genetics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Seattle Genetics in a report on Saturday, June 3rd. Cowen and Company set a $61.00 price objective on Seattle Genetics and gave the stock a “hold” rating in a report on Tuesday, June 6th. J P Morgan Chase & Co reiterated a “hold” rating and issued a $58.00 price objective on shares of Seattle Genetics in a report on Tuesday, June 13th. Finally, Cann reiterated a “hold” rating on shares of Seattle Genetics in a report on Monday, June 19th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Seattle Genetics presently has a consensus rating of “Hold” and a consensus target price of $62.29.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.